Rare Kidney Disorders: Future Miracle Drugs
Kidney disorders are one of the most common causes of mortality, accounting for 850 million deaths, per year, across the globe. Over 300 congenital, inherited and acquired disorders fall under the umbrella of rare kidney disorders. It is worth mentioning that these set of disorders are known to have a serious effect on the general kidney functioning, often lowering its ability to filter out waste and fluids from the blood. In recent years, several drugs targeting rare kidney disorders have received the FDA approval; therapies in the current pipeline are being developed to target ~15 disease indications.
Rare Kidney Disorder Drugs: Current Market Landscape
The pipeline features more than 125 drugs indicated for rare kidney disorder that are either approved / are currently being evaluated across different phases of development or are in late stages of development. The below figure presents the distribution of drugs indicated for rare kidney disorder, based on their phase of development. As can be observed in the figure, most of the rare kidney disorders drug candidates are in phase II of clinical development, followed by those approved. It is worth mentioning that, till date, multiple rare kidney disorder drug candidates have received special drug designations from regulatory authorities of different regions. It is worth highlighting that several other drugs are currently being evaluated in phase III and phase II/III studies for the treatment of rare kidney disorder indications. Therefore, we believe that the market for rare kidney disorders is likely to grow in the foreseen future.
The Increasing Interest in this Field is also Reflected in Recent Partnership Activity
Over the past few years, there has been a steady increase in the partnership activity within this domain, during the period 2017-2021. It is worth mentioning that the maximum number of partnerships (10) were inked in 2018 and 2019 each. Example of partnership inked since 2021, includes that signed between Advicenne Pharma and FrostPharma (Jan 2022).
It is worth highlighting that there is a significant rise in the interest of stakeholders in rare kidney disorders domain; this can be validated by the increase in partnership and funding activity within this segment. Further, the growing demand for increased efficacy and safety of drugs has compelled the players engaged in this domain to expand their platforms / technologies in order to accommodate the future needs of their clients. Owing to the numerous drugs being approved for rare kidney disorders, we believe that this market will experience significant growth in the near future. You can also check out our report on rare kidney disorders by visiting ‘Rare Kidney Diseases Market‘ section.